Literature DB >> 8443300

Ten-year experience with artificial pneumoperitoneum for end-stage, drug-resistant pulmonary tuberculosis.

A T Nitta1, M D Iseman, J D Newell, L A Madsen, M Goble.   

Abstract

Artificial pneumoperitoneum is a form of collapse therapy that was used in the treatment of cavitary pulmonary tuberculosis before the availability of antimycobacterial chemotherapy. We report a series of cases of far-advanced pulmonary disease due to multiple-drug-resistant Mycobacterium tuberculosis, wherein artificial pneumoperitoneum with or without subsequent surgical extirpation was used as an adjunct to chemotherapy. Overall, among these desperate cases, therapeutic pneumoperitoneum provided no clear benefit.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8443300     DOI： 10.1093/clind/16.2.219

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

1.  Therapeutic pneumoperitoneum in a patient with pulmonary tuberculosis and persistent fever.

Authors:  M Antoniou; D Chloros; D Spyratos; P Giouleka; L Sichletidis
Journal:  BMJ Case Rep       Date:  2011-02-02

2.  Chronically increased intra-abdominal pressure: validating a model.

Authors:  Theodossis S Papavramidis; Thomai P Lazou; Angeliki Cheva; Orestis J Gamvros
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

3.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

4.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

Review 5.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

6.  The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile.

Authors:  I Just; J Selzer; C von Eichel-Streiber; K Aktories
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.